In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schott opens new China pharma packaging plant

This article was originally published in Scrip

Executive Summary

Schott has opened a new plant for the production of glass pharmaceutical packaging on its existing site in Suzhou, China. The facility is the first of its kind to be set up in the country by a foreign firm, and will supply primary containers to both domestic and multinational companies. The Chinese market for glass packaging is still dominated by low price products, but demand for Schott's high quality lines is expected to grow along with the overall pharma industry, the German group notes. The 2,500m2 facility has 50 employees and a current annual capacity of more than 100 million ampoules and vials, which can be increased if required.

You may also be interested in...



Japan Nods Include Global First For Duvroq, First Local Biosimilar Humira

Japan’s regulators have approved a large batch of new products, including a novel antibody from Chugai, world-first nods for the country’s second HIF-PH inhibitor and an asthma therapy, and the first Humira biosimilar in Japan – as well as five drugs from Novartis.

Quick Listen: Scrip’s Five Must-Know Things

Join us for a quick audio roundup of five useful things to know from Scrip’s recent coverage of the global biopharmaceutical industry.

Asia Deal Watch: Betta Will Bring Two Agenus Oncology Candidates To Its Market Area

Also, deals involving Immunomic, Replicate, Biocon, DKSH, Genor, G1, Daiichi Sankyo, Esperion, Alteogen, Gelesis, China Medical System Holdings, Sosei and EverInsight.

Topics

UsernamePublicRestriction

Register

LL082593

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel